Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 13

1.

The immunological and virological consequences of planned treatment interruptions in children with HIV infection.

Klein N, Sefe D, Mosconi I, Zanchetta M, Castro H, Jacobsen M, Jones H, Bernardi S, Pillay D, Giaquinto C, Walker AS, Gibb DM, De Rossi A; Paediatric European Network for Treatment of AIDS 11 Trial Team.

PLoS One. 2013 Oct 23;8(10):e76582. doi: 10.1371/journal.pone.0076582. eCollection 2013.

PMID:
24194841
[PubMed - in process]
Free PMC Article
2.

Lopinavir/ritonavir monotherapy as a nucleoside analogue-sparing strategy to prevent HIV-1 mother-to-child transmission: the ANRS 135 PRIMEVA phase 2/3 randomized trial.

Tubiana R, Mandelbrot L, Le Chenadec J, Delmas S, Rouzioux C, Hirt D, Treluyer JM, Ekoukou D, Bui E, Chaix ML, Blanche S, Warszawski J; ANRS 135 PRIMEVA (Protease Inhibitor Monotherapy Evaluation) Study Group.

Clin Infect Dis. 2013 Sep;57(6):891-902. doi: 10.1093/cid/cit390. Epub 2013 Jun 12.

PMID:
23766338
[PubMed - indexed for MEDLINE]
Free Article
3.

Transmitted drug resistance in French HIV-2-infected patients.

Charpentier C, Visseaux B, Bénard A, Peytavin G, Damond F, Roy C, Taieb A, Chêne G, Matheron S, Brun-Vézinet F, Descamps D; ANRS CO5 HIV-2 Cohort.

AIDS. 2013 Jun 19;27(10):1671-4. doi: 10.1097/QAD.0b013e32836207f3.

PMID:
23595155
[PubMed - indexed for MEDLINE]
4.

Dosing rationale for liraglutide in type 2 diabetes mellitus: a pharmacometric assessment.

Ingwersen SH, Khurana M, Madabushi R, Watson E, Jonker DM, Le Thi TD, Jacobsen LV, Tornøe CW.

J Clin Pharmacol. 2012 Dec;52(12):1815-23. doi: 10.1177/0091270011430504. Epub 2011 Dec 15.

PMID:
22174428
[PubMed - indexed for MEDLINE]
5.

Association of prenatal and postnatal exposure to lopinavir-ritonavir and adrenal dysfunction among uninfected infants of HIV-infected mothers.

Simon A, Warszawski J, Kariyawasam D, Le Chenadec J, Benhammou V, Czernichow P, Foissac F, Laborde K, Tréluyer JM, Firtion G, Layouni I, Munzer M, Bavoux F, Polak M, Blanche S; ANRS French Perinatal Cohort Study Group.

JAMA. 2011 Jul 6;306(1):70-8. doi: 10.1001/jama.2011.915.

PMID:
21730243
[PubMed - indexed for MEDLINE]
6.

GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide.

Hegedüs L, Moses AC, Zdravkovic M, Le Thi T, Daniels GH.

J Clin Endocrinol Metab. 2011 Mar;96(3):853-60. doi: 10.1210/jc.2010-2318. Epub 2011 Jan 5.

PMID:
21209033
[PubMed - indexed for MEDLINE]
7.

Response to planned treatment interruptions in HIV infection varies across childhood.

Paediatric European Network for Treatment of AIDS.

AIDS. 2010 Jan 16;24(2):231-41. doi: 10.1097/QAD.0b013e328333d343.

PMID:
20010073
[PubMed - indexed for MEDLINE]
8.

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU).

Marre M, Shaw J, Brändle M, Bebakar WM, Kamaruddin NA, Strand J, Zdravkovic M, Le Thi TD, Colagiuri S; LEAD-1 SU study group.

Diabet Med. 2009 Mar;26(3):268-78. doi: 10.1111/j.1464-5491.2009.02666.x.

PMID:
19317822
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes.

Courrèges JP, Vilsbøll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, Verhoeven R, Bugáñová I, Madsbad S.

Diabet Med. 2008 Sep;25(9):1129-31. doi: 10.1111/j.1464-5491.2008.02484.x. No abstract available.

PMID:
19183322
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus.

Vilsbøll T, Brock B, Perrild H, Levin K, Lervang HH, Kølendorf K, Krarup T, Schmitz O, Zdravkovic M, Le-Thi T, Madsbad S.

Diabet Med. 2008 Feb;25(2):152-6. doi: 10.1111/j.1464-5491.2007.02333.x. Epub 2008 Jan 14.

PMID:
18201212
[PubMed - indexed for MEDLINE]
11.

Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes.

Vilsbøll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, Courrèges JP, Verhoeven R, Bugánová I, Madsbad S.

Diabetes Care. 2007 Jun;30(6):1608-10. Epub 2007 Mar 19. No abstract available.

PMID:
17372153
[PubMed - indexed for MEDLINE]
12.

First stages of biofilm formation: characterization and quantification of bacterial functions involved in colonization process.

Le Thi TT, Prigent-Combaret C, Dorel C, Lejeune P.

Methods Enzymol. 2001;336:152-9. No abstract available.

PMID:
11398396
[PubMed - indexed for MEDLINE]
13.

Developmental pathway for biofilm formation in curli-producing Escherichia coli strains: role of flagella, curli and colanic acid.

Prigent-Combaret C, Prensier G, Le Thi TT, Vidal O, Lejeune P, Dorel C.

Environ Microbiol. 2000 Aug;2(4):450-64.

PMID:
11234933
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk